Akari Therapeutics plans clinical trials for AKTX-101.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: Globenewswire
Akari Therapeutics PLC saw a price increase of 5.15% as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The company announced plans to initiate clinical trials for its innovative drug AKTX-101, targeting cancer treatment, which has generated excitement in the market.
This development could position Akari Therapeutics favorably in the oncology sector, potentially leading to significant advancements in cancer therapies.
Analyst Views on AKTX
Wall Street analysts forecast AKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTX is 3.33 USD with a low forecast of 1.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.254
Low
1.00
Averages
3.33
High
7.00
Current: 0.254
Low
1.00
Averages
3.33
High
7.00
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
